2 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Approved WMOCompleted
To compare the effectiveness of 1) double dose of cyclopentolate and 2) one dose of cyclopentolate and one dose of tropicamide with 3 days, total 5 doses atropine.To investigate whether one dose of tropicamide combined with cyclopentolate is as…